Add BrightSurf on Google Email

Researchers developed a small molecule that makes immunotherapy available to all cancer patients

Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.

SourceTel-Aviv University·JournalJournal for ImmunoTherapy of Cancer·DateAug 8, 2022

CRISPR therapeutics can damage the genome

A new study from Tel Aviv University found that CRISPR therapeutics can lead to a significant loss of genetic material in treated cells, potentially destabilizing the genome and promoting cancer. The researchers detected up to 10% of cells with lost chromosomes, highlighting the need for extra care when using this technology.

SourceTel-Aviv University·JournalNature Biotechnology·DateJul 24, 2022

Gwangju Institute of Science and Technology researchers develop a tool for studying inflammatory diseases related to COVID-19

Researchers at Gwangju Institute of Science and Technology have developed a new bioinformatics pipeline, CRESSP, to investigate the mechanism underlying autoimmune diseases following SARS-CoV-2 infection. The tool identified potential epitopes responsible for COVID-related autoimmune diseases and predicted cross-reactive epitopes of di...

SourceGIST (Gwangju Institute of Science and Technology)·JournalBriefings in Bioinformatics·TypeComputational simulation/modeling·DateMay 16, 2022

Model finds COVID-19 deaths among elderly may be due to genetic limit on cell division

A University of Washington model found that the body's ability to create cloned immune cells falls significantly with age, leading to increased susceptibility to COVID-19 in the elderly. The study suggests that genetic limits on cell division may play a role in the devastating effects of COVID-19 on older adults.

SourceUniversity of Washington·JournalEBioMedicine·TypeData/statistical analysis·DateMay 6, 2022

Findings open way for personalised MS treatment

Researchers at Karolinska Institutet have developed a method to identify the immune cells involved in autoimmune diseases and identified four new target molecules for personalized treatment of multiple sclerosis. This approach could lead to more precise treatments with fewer side effects, potentially benefiting other autoimmune diseases.

SourceKarolinska Institutet·JournalScience Advances·DateApr 27, 2022

The nanodrug that attacks the cancer twice A single nanoparticle does two jobs: enhancing the effectiveness of chemotherapy and reinvigorating the immune system

Researchers at Tel Aviv University developed a drug delivery system based on lipid nanoparticles that utilize RNA to boost personalized cancer care. The nanodrug enhances chemotherapy effectiveness and reinvigorates the immune system, increasing sensitivity to cancer cells.

SourceTel-Aviv University·JournalScience Advances·DateApr 4, 2022

IgA antibodies seem to protect unvaccinated against COVID-19

A University of Gothenburg study found that IgA antibodies present in the respiratory tract protected healthcare workers from contracting COVID-19. The research, published in the European Journal of Immunology, suggests that these antibodies may play a crucial role in preventing severe illness and hospitalization.

SourceUniversity of Gothenburg·JournalEuropean Journal of Immunology·TypeObservational study·DateMar 24, 2022

Penn-Developed CAR T Cells Suppress GI Solid Tumor Cells, Without Toxicity to Healthy Tissue, in Preclinical Research

Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.

New way viruses trigger autoimmunity discovered

Researchers discovered a viral infection can trigger autoimmunity in mice by disrupting the thymus's screening process for self-destructive T cells. Infection with murine roseolovirus led to autoimmune gastritis months later, highlighting a previously unknown way viruses can trigger autoimmunity.

SourceWashU Medicine·JournalJournal of Experimental Medicine·TypeExperimental study·DateFeb 28, 2022

Scientists demonstrate utility of Bilateral Tumor Model for evaluating anti-cancer T-cell responses

A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.

SourceTokyo University of Science·JournalFrontiers in Immunology·TypeExperimental study·DateJan 19, 2022

Research published in AACR journal and presented at ASH identifies potential approach to mitigate CAR T-cell therapy toxicity

A novel approach may reduce the serious adverse effect of cytokine release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy. Supressing interferon gamma (IFNγ) appears to prevent activation of macrophages and other immune cells that drive the syndrome without impacting CAR T-cell efficacy.

SourceAmerican Association for Cancer Research·JournalBlood Cancer Discovery·DateDec 15, 2021

When cancer “met” its match: New study shows metformin-dependent antitumor immunity

A recent study led by Okayama University scientists found that metformin activates a subset of immune cells called CD8+ T-lymphocytes to attack and kill tumor cells. The study revealed that metformin increases the production of reactive oxygen species in these cells, which activates growth pathways and allows for proliferation.

SourceOkayama University·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateNov 12, 2021

Solving mystery of rare cancers directly caused by HIV

A team of scientists from the University of Pittsburgh and National Cancer Institute discovered why HIV is rarely the direct cause of cancer. The research found that it requires a specific series of events involving changes in HIV and additional mutations in human genes, resulting in T cell lymphomas. However, the occurrence is rare, a...

SourceUniversity of Pittsburgh·JournalScience Advances·DateOct 13, 2021

Killer T cells could be recruited to ignite immune response against cancer, new study suggests

Researchers have discovered a way to bring cancer-killing T cells to bear against a specific type of colorectal cancer, showing promising results. The findings may represent a therapeutic strategy to target other types of cancers, and the next step is to further explore how T cells become activated in the tumor environment.

SourceUniversity of Alberta Faculty of Medicine & Dentistry·JournalJournal of Experimental Medicine·DateOct 8, 2021

Cancer breakthrough: Exercise may stop disease in its tracks

A clinical trial found that obese prostate cancer patients who underwent regular exercise training for 12 weeks had increased levels of anti-cancer myokines, which suppressed tumour growth and helped fight cancerous cells. The study suggests exercise may be a key weapon in cancer patients' battle against the disease.

SourceEdith Cowan University·JournalMedicine & Science in Sports & Exercise·TypeRandomized controlled/clinical trial·DateOct 4, 2021

Existing drug may help improve responses to cellular therapies in advanced leukemias

Researchers at the University of Pennsylvania School of Medicine have identified a new mechanism of resistance in advanced chronic lymphocytic leukemia (CLL) patients to CAR T cell therapy. They found that inhibiting the BET protein with the small molecule inhibitor JQ1 can reinvigorate exhausted T cells and increase their production.

SourceUniversity of Pennsylvania School of Medicine·JournalJournal of Clinical Investigation·TypeExperimental study·DateAug 16, 2021